Stock listing

Alkermes Plc

Selected listing: 8AK · SWB · EUR · DE

Alkermes Plc (Stuttgart:8AK), Health Technology. Latest release Sep 21, 2026: Alkermes Announces Positive Phase 1b Results Demonstrating Clinical…

8AK:SWBEURDEUpdated October 9, 2026

Ticker: Stuttgart:8AK
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Stuttgart
Currency: EUR

About Alkermes Plc

The company focuses on developing innovative medicines for patients with serious mental health conditions and addiction. Alkermes is committed to improving patient outcomes through its research and development efforts.

Latest news from Alkermes Plc

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

September 21, 2026

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

September 16, 2026

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

September 10, 2026

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

August 24, 2026

Alkermes plc Reports Second Quarter 2026 Financial Results

July 28, 2026

All Alkermes Plc news →

Events

Replays

Alkermes plc (ALKS) Q2 2026 Earnings Call
Tue, Jul 28, 2026 · 08:00 AM ET
Watch
Alkermes plc (ALKS) Q1 2026 Earnings Call
Tue, May 05, 2026 · 08:00 AM ET
Watch
Alkermes plc (ALKS) Q4 2026 Earnings Call
Wed, Feb 25, 2026 · 08:00 AM ET
Watch

Research Alkermes Plc

Alkermes Plc company profile

View the public company page for Alkermes Plc on 6ix.

Alkermes Plc news

Read company news and market updates connected to Alkermes Plc.

Alkermes Plc investor events

Find investor webinars, events, and replay context for Alkermes Plc.